Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Nuvation Bio r&d expenses
Research and development expenses are spending on new products and technology.
Nuvation Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $128.85M, up 18.2% year over year. For fiscal 2025 it was $115.11M, up 16.1% from the year before. The highest annual figure on record is $115.11M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.11M | +16.1% |
| FY2024 | Dec 31, 2024 | $99.12M | +39.0% |
| FY2023 | Dec 31, 2023 | $71.29M | -18.8% |
| FY2022 | Dec 31, 2022 | $87.82M | +27.2% |
| FY2021 | Dec 31, 2021 | $69.04M | +111.8% |
| FY2020 | Dec 31, 2020 | $32.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.66M | +12.1% |
| Q1 FY2026 | Mar 31, 2026 | $35.05M | +42.5% |
| Q4 FY2025 | Dec 31, 2025 | $34.30M | +17.1% |
| Q3 FY2025 | Sep 30, 2025 | $28.85M | +4.0% |
| Q2 FY2025 | Jun 30, 2025 | $27.36M | -6.4% |
| Q1 FY2025 | Mar 31, 2025 | $24.60M | +91.6% |
| Q4 FY2024 | Dec 31, 2024 | $29.30M | +90.9% |
| Q3 FY2024 | Sep 30, 2024 | $27.73M | +49.4% |
| Q2 FY2024 | Jun 30, 2024 | $29.25M | +57.3% |
| Q1 FY2024 | Mar 31, 2024 | $12.84M | -31.6% |
| Q4 FY2023 | Dec 31, 2023 | $15.35M | -9.0% |
| Q3 FY2023 | Sep 30, 2023 | $18.56M | -12.8% |
| Q2 FY2023 | Jun 30, 2023 | $18.59M | -35.7% |
| Q1 FY2023 | Mar 31, 2023 | $18.79M | -9.4% |
| Q4 FY2022 | Dec 31, 2022 | $16.87M | -23.3% |
| Q3 FY2022 | Sep 30, 2022 | $21.29M | +24.4% |
| Q2 FY2022 | Jun 30, 2022 | $28.92M | +106.1% |
| Q1 FY2022 | Mar 31, 2022 | $20.73M | +30.5% |
| Q4 FY2021 | Dec 31, 2021 | $22.00M | +135.7% |
| Q3 FY2021 | Sep 30, 2021 | $17.12M | +98.5% |
| Q2 FY2021 | Jun 30, 2021 | $14.03M | +91.1% |
| Q1 FY2021 | Mar 31, 2021 | $15.88M | +117.7% |
| Q4 FY2020 | Dec 31, 2020 | $9.34M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.63M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.35M | – |
| Q1 FY2020 | Mar 31, 2020 | $7.30M | – |
See a number that looks wrong?